Literature DB >> 30788295

Antifungal Susceptibility of Candida Species Isolated from Horticulturists with Onychomycosis in Piauí, Brazil.

Mitra Mobin1, Maria Walderez Szeszs2, Juliana Possatto Takahashi2, Marilena Martins2, Daise Damaris Carnietto de Hippólito2, Jhonatas Cley Santos Porto1, João Batista Teles1, Sidney Gonçalo de Lima3, Marcia de Souza Carvalho Melhem2.   

Abstract

BACKGROUND: We aimed to assess susceptibility pattern of Candida species isolated from horticulturists with onychomycosis to four antifungal drugs and to compare the effectiveness of conventional identification methods with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF MS).
METHODS: This study was conducted in a community garden located in Teresina, State of Piauí, Brazil, in the year 2014. The samples were identified through phenotypic methods and per MALDI-TOF MS, being used PCR as definitive identification test. The susceptibility pattern to four antifungal drugs was determined according to Clinical and Laboratory Standards Institute (CLSI).
RESULTS: Fourteen clinical isolates from seven different species were identified by the phenotypic method and by MALDI-TOF MS, with an observed concordance of 71.4% between the two methods. C. albicans (28.6%), C. parapsilosis (21.4%), C. guilliermondii and C. metapsilosis (both with 14.3%) were the most frequent species. With the exception of C. krusei, all species were sensitive to the tested antifungal.
CONCLUSION: This is the first study of antifungal susceptibility of Candida in Piauí, Brazil. With the exception of C. krusei, no species showed resistance to the antifungal drugs used. This study suggests constants updates from the public databases used in MALDI-TOF MS to provide a rapid and accurate mycological diagnosis.

Entities:  

Keywords:  Candida; Matrix-assisted laser desorption/ionization mass spectrometry; Onychomycosis; Susceptibility

Year:  2018        PMID: 30788295      PMCID: PMC6379607     

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.429


Introduction

Onychomycosis is an infection resulting from the nail plate invasion by dermathophyte and, less frequently, by species of Candida, Aspergillus, Scopulariopsis, Fusarium and Acremonium. This disease is currently considered a public health problem because it affects about 10% of the world population and accounts for over 50% of all nail disorders (1). Candida species are the second most common cause of onychomycosis, mainly affecting the fingernails. Although C. albicans is the most common etiological agent, other non-albicans species, such as C. guilliermondii, are currently gaining prominence in the medical field as nail mycosis agents (2, 3). The susceptibility to antifungal drugs varies significantly among Candida species, as well as for the same species in different regions. Therefore, there is a constant need to determine antifungal susceptibility patterns of these organisms (3). There is no report on susceptibility patterns of onychomycosis agents in Teresina- Piauí, Brazil. This research aimed to determine the susceptibility patterns of Candida species isolated from horticulturists with onychomycosis to four antifungal drugs and to compare the effectiveness of the conventional identification methods with MALDI-TOF MS.

Materials and Methods

Study Population and Location

This study was conducted in the year 2014 with horticulturists from a community garden located in Teresina, Piauí, Brazil, and approved by the Ethics in Research Committee of University Center UNINOVAFAPI, under CAAE 02070043000-10, obeying the Resolution 466/12. Participated in this research the horticulturists with at least 12 months of work, that presenting nail disorders and that sign the Informed Consent Form.

Species collection and identification

Before initiating the procedure, the collection area was properly cleaned followed by antisepsis with 70% ethanol. Samples were collected during the dry and rainy seasons at intervals of 7 to 10 days. Posteriorly, the samples were transported to the Research Laboratory of the University Center UNINOVAFAPI – Piauí and to the Mycology Nucleus of the Adolfo Lutz Institute - São Paulo, for phenotypic identification and biochemical tests, respectively. The phenotypic identification was carried out according to to the identification keys described by (4–6). For the biochemical test was used the commercial system API®/ID32 (bioMérieux, Fr), following the manufacturer’s instructions. The analysis per MALDI-TOF MS (VITEK MS, bio Mérieux, France) was carried out at the Mycology Nucleus of the Adolfo Lutz Institute - São Paulo, using a Microflex LT Mass spectrometer (Bruker Daltonik GmbH) (7). When there was a discrepancy between the results obtained by MALDI-TOF MS and by conventional identification, PCR was used with specific primers with starting sequences indicated in literature (8).

Antifungal susceptibility test

In vitro antifungal susceptibility to four antifungal drugs – Fluconazole (Eurofarma, Brazil), Terbinafine (Genix Indústria Farmacêutica Ltda, Brazil), Itraconazole (Eurofarma, Brazil), and Amphotericin B (Sigma, S. Louis, EUA) – was determined through broth microdilution assay (9). The standard strains C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were used as controls (10). All tests were performed in triplicate. The minimum inhibitory concentration (MIC) values were interpreted according to the new CLSI species-specific clinical breakpoints (CBPs) established for fluconazole against Candida species. For Candida species with no available CBPs, MIC was compared to the values available in literature. When it was not possible to assess MIC through breakpoint, epidemiological cutoff values (ECVs) were used (11).

Statistical analysis

The entire statistical analysis was performed using the IBM SPSS statistics software, version 21.0 (Chicago, IL, USA). The variables were compared using Fisher’s exact test with significance level of 5%. Values of P<0.05 were considered significant for the analysis.

Results

Fourteen clinical isolates from seven different species were identified as onychomycosis etiological agents in the horticulturists evaluated, being C. albicans with 28.6% (N=4) the most frequent species, followed by C. parapsilosis with 21.4% (N=3), C. guilliermondii and C. metapsilosis both with 14.3% (N=2), C. africana, C. krusei and C. rugosa both with 7.1% (N=1). All yeasts were identified by the phenotypic method and MALDI-TOF MS, with a concordance of 71.4% between the two methods. The results obtained by the classical methodology differed from MALDI-TOF MS only for C. albicans, C. parapsilosis and C. tropicalis, identified by MALDI-TOF MS as C. africana, C. metapsilosis, and C. rugosa, respectively. Concerning the susceptibility of Candida isolates identified in the present study to the four anti-fungal tested, only C. krusei showed resistance to fluconazole, with MIC of 64 μg/ml. C. parapsilosis (samples 11 and 30) presented low MIC values for all antifungal drugs analyzed while C. guilliermondii (sample 54) obtained the highest MIC values for all drugs, except fluconazole. The remaining yeasts presented very similar MIC values (Table 1).
Table 1:

Antifungal drugs susceptibility in Candida species isolated from horticulturist with onychomycosis

SamplesSpeciesAntifungals / MIC (μg/ml)
FLC*ITC**TRB***AMB****
9Candida krusei640.1241
11Candida parapsilosis20.120.120.5
18Candida africana0.120.0310.25
30Candida parapsilosis20.120.120.5
34Candida albicans20.0150.50.25
43Candida metapsilosis40.120.250.5
44Candida albicans20.060.250.5
54Candida guilliermondii80.541
58Candida guilliermondii40.2541
63Candida parapsilosis0.50.060.061
71Candida albicans0.120.0150.250.25
89Candida albicans0.250.030.50.5
90Candida rugosa10.1241
104Candida metapsilosis20.060.120.5
Candida parapsilosis ATCC- 2201920.060.060.5
Candida krusei ATCC- 6258640.1241

Source: Laboratory of Research UNINOVAFAPI and Mycology Nucleus of the Adolfo Lutz Institute –SP

Fluconazole

Itraconazole

Terbinafine

Amphotericin B

Antifungal drugs susceptibility in Candida species isolated from horticulturist with onychomycosis Source: Laboratory of Research UNINOVAFAPI and Mycology Nucleus of the Adolfo Lutz Institute –SP Fluconazole Itraconazole Terbinafine Amphotericin B

Discussion

Onychomycosis is the most common dermatomycosis in the world, affecting all populations and ages. Candida spp. is the second most frequent cause of nail mycosis in several geographical regions, affecting mainly fingernails. C. albicans and C. parapsilosis were the most frequently isolated species in this study (2,12, 13). There are no many studies addressing C. guilliermondii, the third most frequently found species in this study, as onychomycosis agent. Making an accurate and rapid diagnosis is critical for a successful treatment of onychomycosis, but in many laboratories, this is not possible due to limited resources available. In terms of rapid, reliability and economy, MALDI-TOF MS is increasingly conquering space, not only in mycosis diagnosis but also in the diagnosis of pathologies caused by other types of microorganisms (12, 14). MALDI-TOF MS analysis takes only few minutes and the execution protocols are simple, allowing high throughput of clinical samples. Species identification using this method depends on database consistency and on the number of spectra of different isolates belonging to the same species (15). Yeast species identification was analyzed by the traditional method and MALDI-TOF MS and concluded that the latter promoted time saving and greater effectiveness (16). ITS region sequencing was used as reference method in performance analysis and verified 94% agreement between the identification results by MALDI-TOF MS and ITS and only 84.3% between classic analysis and the reference method. MALDI-TOF MS cannot distinguish C. africana from C. albicans, requiring more precise molecular methods for such differentiation (12). Fortunately, the literature reports an effective method for distinguishing C. albicans from C. africana, based on the hyphal wall protein 1 (hwp1) gene in polymerase chain reaction (PCR) -based assay, where the hwp1 gene from C. africana contains 750bp and the typical C. albicans comprises 941bp (17). In this study, the MALDI-TOF MS was able to determine critical species, such as C. africana and C. metapsilosis, indistinguishable within each complex according to phenotypic methods. The divergences between the results of this study and the other findings (12) can be justified by the inconsistency of the public databases, reaffirming the need for continuous updating of such databases (7,18). In relation to the four antifungal drugs tested, itraconazole and terbinafine are used in skin mycosis treatment whereas amphotericin B is recommended for more severe cases of fungal infections (19). Fluconazole is the most commonly used agent for the prophylaxis and treatment of candidiasis, considering its low toxicity, high solubility and wide tissue distribution. Due to these pharmacological characteristics added to the emergence of azole-resistant Candida species, one study has synthesized, from changes in the structure of fluconazole, two compounds named aryl-1,2,4-triazole-3-yl analogue of fluconazole (ATTAF-1) and aryl-1,2,4-triazole-3-yl (thio) analogues of fluconazole-2 (ATTAF-2). These new azole compounds showed low toxicity in human cells and effective anti-Candida activity in vitro both alone and in combination with fluconazole, proving to be an effective alternative for the treatment of Candida spp. infections (20). Onychomycosis by yeasts does not always respond well to topical treatment and systemic treatment is necessary in those cases. The drugs used in systemic treatment belong to two big pharmaceutical groups: allylamines and azole derivatives. Terbinafine is an allylamine effective in the treatment of onychomycosis by Candida species, mainly C. parapsilosis (21,2). Unfortunately, studies on yeast susceptibility in onychomycosis cases are scarce in literature and data is usually reported together with yeasts that cause mucocutaneous, urinary and bloodstream infections. In this manner, the assessment of just onychomycosis strains is impaired. With the exception of C. krusei, whose intrinsic resistance to fluconazole is already known, in this study no resistance was observed to other anti-fungal drugs. However, the MICs obtained for C. guilliermondii (case 54) against the four antifungal drugs tested must be highlighted, once they were the highest MICs obtained for a single isolate. C. guilliermondii is currently a species that raises great interest and concern among medical doctors because of the emergence of strains with multi-resistance to azoles, terbinafine and amphotericin B. High values of fluconazole and terbinafine were already observed for a single isolate of this species (21, 22).

Conclusion

This is the first study of antifungal susceptibility of Candida spp. in Piauí, Brazil. With the exception of Candida krusei, no species showed resistance to the four antifungal drugs used. This study suggests constants updates from the public databases used in MALDI-TOF MS to provide a rapid and accurate mycological diagnosis.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.
  15 in total

1.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

2.  Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.

Authors:  M A Pfaller; A Espinel-Ingroff; E Canton; M Castanheira; M Cuenca-Estrella; D J Diekema; A Fothergill; J Fuller; M Ghannoum; R N Jones; S R Lockhart; E Martin-Mazuelos; M S C Melhem; L Ostrosky-Zeichner; P Pappas; T Pelaez; J Peman; J Rex; M W Szeszs
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

3.  Identification of yeast isolated from dermatological patients by MALDI-TOF mass spectrometry.

Authors:  Florian Seyfarth; Cornelia Wiegand; Marcel Erhard; Yvonne Gräser; Peter Elsner; Uta-Christina Hipler
Journal:  Mycoses       Date:  2011-08-17       Impact factor: 4.377

4.  Lack of Candida africana and Candida dubliniensis in vaginal Candida albicans isolates in Turkey using HWP1 gene polymorphisms.

Authors:  Ramazan Gumral; Banu Sancak; Ahmet Barış Guzel; Mehmet Ali Saraçlı; Macit Ilkit
Journal:  Mycopathologia       Date:  2011-03-06       Impact factor: 2.574

5.  Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.

Authors:  A K Gupta; T Gregurek-Novak
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

6.  Evaluation of matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry for identification of Candida parapsilosis, C. orthopsilosis and C. metapsilosis.

Authors:  I Quiles-Melero; J García-Rodríguez; A Gómez-López; J Mingorance
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-06       Impact factor: 3.267

7.  Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.

Authors:  Meng Xiao; Xin Fan; Sharon C-A Chen; He Wang; Zi-Yong Sun; Kang Liao; Shu-Lan Chen; Yan Yan; Mei Kang; Zhi-Dong Hu; Yun-Zhuo Chu; Tie-Shi Hu; Yu-Xing Ni; Gui-Ling Zou; Fanrong Kong; Ying-Chun Xu
Journal:  J Antimicrob Chemother       Date:  2014-12-03       Impact factor: 5.790

8.  Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Authors:  O Bader; M Weig; L Taverne-Ghadwal; R Lugert; U Gross; M Kuhns
Journal:  Clin Microbiol Infect       Date:  2010-12-03       Impact factor: 8.067

9.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

10.  A study of onychomycosis in patients attending a dermatology center in Tehran, Iran.

Authors:  M Soltani; A R Khosravi; H Shokri; A Sharifzadeh; A Balal
Journal:  J Mycol Med       Date:  2015-05-04       Impact factor: 2.391

View more
  1 in total

1.  Virulence Factors and Antifungal Susceptibility in Candida Species Isolated from Dermatomycosis Patients.

Authors:  Victor Galvão Mello; Heloisa Escudeiro; Ana Carolina Villas Bôas Weckwerth; Maria Izilda Andrade; Ana Elisa Fusaro; Eloise Brasil de Moraes; Luciana da Silva Ruiz; Ida Maria Foschiani Dias Baptista
Journal:  Mycopathologia       Date:  2020-11-20       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.